Swiss National Bank held its stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 113,700 shares of the biopharmaceutical company’s stock at the end of the third quarter. Swiss National Bank owned about 0.15% of Inovio Pharmaceuticals worth $1,060,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. State Board of Administration of Florida Retirement System increased its position in Inovio Pharmaceuticals by 11.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 26,730 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 2,768 shares during the last quarter. Stoneridge Investment Partners LLC increased its position in Inovio Pharmaceuticals by 44.4% in the third quarter. Stoneridge Investment Partners LLC now owns 252,376 shares of the biopharmaceutical company’s stock valued at $2,352,000 after buying an additional 77,636 shares during the last quarter. Tocqueville Asset Management L.P. increased its position in Inovio Pharmaceuticals by 1.7% in the second quarter. Tocqueville Asset Management L.P. now owns 71,600 shares of the biopharmaceutical company’s stock valued at $662,000 after buying an additional 1,200 shares during the last quarter. Allianz Asset Management AG purchased a new position in Inovio Pharmaceuticals during the second quarter valued at approximately $1,261,000. Finally, State Street Corp increased its position in Inovio Pharmaceuticals by 20.9% in the second quarter. State Street Corp now owns 2,506,096 shares of the biopharmaceutical company’s stock valued at $23,157,000 after buying an additional 433,867 shares during the last quarter. Hedge funds and other institutional investors own 28.89% of the company’s stock.
Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) opened at 6.38 on Friday. Inovio Pharmaceuticals, Inc. has a 52-week low of $5.70 and a 52-week high of $11.69. The stock has a 50 day moving average price of $6.89 and a 200-day moving average price of $8.14. The firm’s market cap is $472.50 million.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.02. Inovio Pharmaceuticals had a negative return on equity of 39.93% and a negative net margin of 199.99%. The company had revenue of $12.54 million for the quarter, compared to analysts’ expectations of $5.16 million. During the same period in the prior year, the company posted ($0.08) EPS. The firm’s revenue was down 48.3% compared to the same quarter last year. On average, equities analysts anticipate that Inovio Pharmaceuticals, Inc. will post ($0.96) EPS for the current fiscal year.
A number of brokerages have recently issued reports on INO. Brean Capital began coverage on Inovio Pharmaceuticals in a report on Tuesday, October 4th. They issued a “buy” rating and a $18.00 price target on the stock. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Inovio Pharmaceuticals in a report on Wednesday, October 26th. Stifel Nicolaus cut their price target on Inovio Pharmaceuticals to $11.00 and set a “buy” rating on the stock in a report on Monday, October 24th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $13.00 price target (down from $31.00) on shares of Inovio Pharmaceuticals in a report on Wednesday, October 26th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $13.23.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO).